This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …

Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Summary Introduction Continued SARS-CoV-2 infection among immunocompromised
individuals is likely to play a role in generating genomic diversity and the emergence of …

No specific antiviral drugs have been approved for the treatment of COVID-19. This study
aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter …